Brief: Eagle Pharmaceuticals Announces Licensing Agreement With Aop Orphan For U.S. Commercial Rights To Landiolol, A Beta-1 Adrenergic Blocker
09/08/2021 11:47
Aug 9 (Reuters) - Eagle Pharmaceuticals Inc EGRX.O :
* EAGLE PHARMACEUTICALS ANNOUNCES LICENSING AGREEMENT WITH
AOP
ORPHAN FOR U.S. COMMERCIAL RIGHTS TO LANDIOLOL, A BETA-1
ADRENERGIC BLOCKER
* EAGLE PHARMACEUTICALS INC - ANTICIPATES FILING NEW DRUG
APPLICATION ("NDA") IN Q1 2022
* EAGLE PHARMACEUTICALS INC - COMPANY EXPECTS FIVE YEARS OF
NEW
CHEMICAL ENTITY EXCLUSIVITY
* EAGLE PHARMACEUTICALS INC - POISED TO FACILITATE
REGULATORY
PATHWAY FOR APPROVAL IN U.S. BASED ON EXISTING DATA FROM
JAPANESE AND EUROPEAN STUDIES
* EAGLE PHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT,
EAGLE WILL
FACILITATE U.S. REGULATORY PATHWAY FOR APPROVAL OF LANDIOLOL
* EAGLE PHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT,
EAGLE WILL
FACILITATE U.S. REGULATORY PATHWAY FOR APPROVAL OF LANDIOLOL
* EAGLE PHARMACEUTICALS INC - WILL BE RESPONSIBLE FOR U.S.
COMMERCIALIZATION OF PRODUCT UPON APPROVAL
* EAGLE PHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT,
EAGLE WILL
MAKE AN UPFRONT PAYMENT OF $5 MILLION
Source text for Eikon: ID:nBwc9nGzra
Further company coverage: EGRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq